A prospective, multicentre, open-label, randomised, phase 2 study to evaluate efficacy and safety of masitinib in combination with gemcitabine or carboplatin or capecitabine in patients with a metastatic or locally advanced breast cancer (all hormonal status tumour except triple negative tumour) and who relapsed after a first line chemotherapy.

Trial Profile

A prospective, multicentre, open-label, randomised, phase 2 study to evaluate efficacy and safety of masitinib in combination with gemcitabine or carboplatin or capecitabine in patients with a metastatic or locally advanced breast cancer (all hormonal status tumour except triple negative tumour) and who relapsed after a first line chemotherapy.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 May 2017

At a glance

  • Drugs Masitinib (Primary) ; Capecitabine; Carboplatin; Gemcitabine
  • Indications Advanced breast cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors AB Science
  • Most Recent Events

    • 13 May 2017 This trial has been discontinued in Spain and completed in Greece (End date:2017-02-11) as per European Clinical Trials Database record.
    • 31 Jul 2015 New source identified and integrated (European Clinical Trials Database; EudraCT2010-022646-24).
    • 02 Jul 2015 In July 2015, an interim analysis was conducted by the DSMB; it was recommended that the study continue as planned, according to an AB Science media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top